NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
The [18F]SynVest-1 radiotracer targets the synaptic vesicle glycoprotein 2A (SV2A) and is a proxy of presynaptic density. Parkinson's disease is associated with synaptic dysfunction. Here we investigated synaptic density via the [18F]SynVest-1 radiotracer in people with PD compared with healthy controls, with reference to how it compares to the previous SV2A radiotracer, [11C]UCB-J. Ten Parkinson's patients and 12 healthy subjects underwent a [18F]SynVest-1 PET scan. We compared non-displaceable binding potential via voxel-wise and volume of interest analysis to investigate group differences. Volume-of-interest-analyses reported lower non-displaceable binding potential in key a priori regions associated with Parkinson's disease, namely the substantia nigra and caudate nucleus (P P 11C]UCB-J radiotracer. The [18F]SynVest-1 radiotracer confirmed lower synaptic density in the Parkinson's disease cohort and adds to the growing evidence of synaptic dysfunction in Parkinson's disease pathology.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.